

Title:
**IMPORTANCE OF ASSESSING FOR CANNABIS USE PRIOR
TO PROPOFOL SEDATION FOR ENDOSCOPY**

Authors:
Antonio Cerezo Ruiz

DOI: 10.17235/reed.2020.7716/2020

Link: [PubMed \(Epub ahead of print\)](#)

Please cite this article as:
Cerezo Ruiz Antonio. IMPORTANCE OF ASSESSING FOR
CANNABIS USE PRIOR TO PROPOFOL SEDATION FOR
ENDOSCOPY. Rev Esp Enferm Dig 2020. doi:
10.17235/reed.2020.7716/2020.



This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

CC 7716

**IMPORTANCE OF ASSESSING FOR CANNABIS USE PRIOR TO PROPOFOL SEDATION FOR
ENDOSCOPY**

Antonio Cerezo-Ruiz

Gastroenterology Dpt. Parejo y Cañero Hospital. Córdoba (Spain)

Correspondence: e-mail: dracerez@hotmail.com

Keywords: Propofol. Cannabis. Endoscopy.

Dear Editor,

Currently, our state Practice Guidelines for sedation in endoscopy procedures¹ recommend a brief pre-assessment in the consults for medical and egg/soy allergies, diseases, treatments and surgeries, as well as oral examination, in order to assess ASA (American Society of Anesthesiology) and Mallampati scores.

Since 2018 we practice deep sedation in our hospital with propofol as sole medication conducted by endoscopist in patients ASA I and II, according to the mentioned Guidelines.

Cannabis and its variations are the most used illicit drug worldwide as just in Spain, unfortunately with increasing usage reported year to year. In our country, the prevalence of significant consumption in the youth was 5,6% (6% men and 5,3% women) in 2019². More recently, we've noticed an increase in patients who require high doses of propofol for their weight without reaching a full anesthetic induction, due certainly to cannabis use.

It's known the interaction of propofol and cannabis at clinical practice levels, not really at basic research. There's scant information regarding that issue, and it's not clearly defined in the data. There is an antagonist effect between $\Delta 9$ tetrahydrocannabinol (THC) and propofol, by blocking their receptors. It's thought to be due a inhibition of

hippocampal gamma-hydroxy-butyrate release by activation of the cannabinoid 2 receptor³, that leads to higher overall propofol dose, therefore with a loss in cardiovascular and respiratory safety.

In my opinión, in addition to a correct medical record, it's crucial to inquire explicitly about the use of cannabis when we suspect it: odd behavior at consults, symptoms such as diarrhoea or vomiting with no other pathologies in the complementary techniques ...

Finally, the main implication in that scenario is that deep sedation for endoscopy should be performed by Anesthesiology no matter what ASA score, according to the increased cardiovascular and respiratory risk.

REFERENCES

1. Igea F, Casellas JA, González-Huix et al. Sedación en endoscopia digestiva. Guía de práctica clínica de la Sociedad Española de Endoscopia Digestiva. Rev Esp Enferm Dig. 2014;106:195-211.
2. Health Ministry. Government of Spain. The ESPAD (European School Survey Project on Alcohol and Other Drugs) report 2019. Available from: https://pnsd.sanidad.gob.es/profesionales/sistemasInformacion/sistemaInformacion/pdf/20201112_Informe_ESPAD_2019_final.pdf [Internet]. [Revised 3 Dec 2020].
3. Woo M, Andrews CN. Implications of cannabis use on sedation for endoscopic procedures. Gastrointest Endosc. 2019;90(4):656-8.